Alizyme(AZM)

Sector:

Pharmaceuticals & Biotechnology

Index:

FTSE Small Cap

Market Cap

£14.37m

Change Today

Price Down-0.70p

Share Price

6.50p

Alizyme's Colal-Pred deal worth up to €42.75m

Date: Friday 27 Jun 2008

LONDON (ShareCast) - Alizyme could net up to €42.75m after it granted an exclusive licence to Norgine for the rights to market Colal-Pred, used to treat ulcerative colitis, in Europe, South Africa, Australia and New Zealand.

The UK drug developer will receive £2m upfront and another €40.75m based on the future development and sales milestones.

Gastroenterology-focused Norgine will cover all commercialisation costs and will pay double digit royalty rates to Alizyme that increase with higher annual net sales levels.

Headline trial results from the European pivotal registration Phase III trial of Colal-Pred in patients with ulcerative colitis are due next month.

Ulcerative colitis is an inflammatory disease of the colon that causes symptoms such as abdominal pain, bleeding, cramping, fatigue and diarrhoea.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Alizyme Market Data

Currency UK Pounds
Share Price 6.50p Price Down
Change Today -0.70p
52 Week High 90.75p
52 Week Low 5.81p
Volume 2,509,077
Shares Issued 221.10m
Market Cap £14.37m
Beta 0.74
RiskGrade 762

Performance Indicators

Compare performance with the sector and the market.
Find out more
Key: vs Market vs Sector
Value
61.52% below the market average61.52% below the market average61.52% below the market average61.52% below the market average61.52% below the market average
78.31% below the sector average78.31% below the sector average78.31% below the sector average78.31% below the sector average78.31% below the sector average
Price Trend
98.85% below the market average98.85% below the market average98.85% below the market average98.85% below the market average98.85% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average
Income Not Available
Growth
31.22% below the market average31.22% below the market average31.22% below the market average31.22% below the market average31.22% below the market average
61.64% below the sector average61.64% below the sector average61.64% below the sector average61.64% below the sector average61.64% below the sector average
Price Chg 6m
98.39% below the market average98.39% below the market average98.39% below the market average98.39% below the market average98.39% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average
P/E Not Available
PEG Not Available
Dividend Yield Not Available
EPS Growth Not Available
Operating Margin
100% below the market average100% below the market average100% below the market average100% below the market average100% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average

Alizyme Dividends

No dividends found

Trades for 29-Aug-2008

Time Volume / Share Price
16:35 3,017 @ 6.50p
16:23 40,000 @ 6.50p
16:18 15,000 @ 6.42p
16:14 5,910 @ 6.42p
16:14 15,000 @ 6.45p

Alizyme Key Personnel

CEO Tim P McCarthy
Chair Brian Richards
Finance Director David Campbell

Digital Look have been voted
"Best Research and Information Provider"

4th Floor, Bankside House, 107 Leadenhall Street, London EC3A 4AF.
Registered in England and Wales (registered no. 3678570).